Caribou Biosciences (CRBU) to Release Earnings on Monday

Caribou Biosciences (NASDAQ:CRBU) will likely be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Caribou Biosciences to post earnings of ($0.33) per share and revenue of $1.9570 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Caribou Biosciences Price Performance

NASDAQ CRBU opened at $1.90 on Monday. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.54. The business has a fifty day moving average price of $1.63 and a two-hundred day moving average price of $1.91. The stock has a market capitalization of $177.59 million, a PE ratio of -1.12 and a beta of 2.54.

Wall Street Analysts Forecast Growth

CRBU has been the topic of several recent research reports. Truist Financial set a $7.00 target price on Caribou Biosciences in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Citigroup lifted their price target on shares of Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 3rd. Finally, HC Wainwright boosted their price objective on Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Caribou Biosciences has a consensus rating of “Hold” and an average price target of $8.00.

Hedge Funds Weigh In On Caribou Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its holdings in Caribou Biosciences by 741.6% in the 1st quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after buying an additional 463,391 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Caribou Biosciences during the first quarter valued at approximately $61,000. Creative Planning bought a new stake in Caribou Biosciences in the second quarter worth $25,000. XTX Topco Ltd purchased a new stake in shares of Caribou Biosciences during the second quarter valued at approximately $133,000. Finally, Jane Street Group LLC increased its holdings in shares of Caribou Biosciences by 64.7% in the 2nd quarter. Jane Street Group LLC now owns 483,610 shares of the company’s stock worth $609,000 after purchasing an additional 189,923 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.